You are here

Article Text

Article menu
Download PDFPDF
Electronic pages
Correspondence response
Response to: ‘MBDA: what is it good for?’ by Yazici et al
  1. Ronald van Vollenhoven1,
  2. Karen Hambardzumyan1,
  3. David Chernoff2,
  4. Rebecca Bolce2
  1. 1Department of Medicine, The Karolinska Institute, Stockholm, Sweden
  2. 2Department of Medicine, Crescendo Bioscience Inc., South San Francisco, California, USA
  1. Correspondence to Dr Ronald F van Vollenhoven, Department of Medicine, The Karolinska Institute, Stockholm 17176, Sweden; ronald.van.vollenhoven{at}ki.se

https://doi.org/10.1136/annrheumdis-2014-206383

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate Drs Yazici and Swearingen's1 interest in our paper.2

    The multi-biomarker disease activity (MBDA) blood test has been validated as a quantitative measurement of rheumatoid arthritis (RA) disease activity.3 The research question addressed in our paper …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Electronic pages
      MBDA: what is it good for?
      Yusuf Yazici Christopher J Swearingen
      Annals of the Rheumatic Diseases 2014; 73 e72-e72 Published Online First: 23 Jul 2014. doi: 10.1136/annrheumdis-2014-206252